XML 29 R11.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value Measurements
12 Months Ended
Dec. 31, 2022
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The Company has certain financial assets and liabilities recorded at fair value which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance prioritizes the inputs used in measuring fair value into the following hierarchy:

Level 1- Quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2- Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable; and

Level 3- Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.

The following tables summarize the assets measured at fair value on a recurring basis (in thousands):

December 31, 2022
TotalLevel 1Level 2Level 3
Assets
Cash and cash equivalents:
Cash$53,033 $53,033 $— $— 
Money market funds174,262 174,262 — — 
U.S. Agency bonds7,965 — 7,965 — 
Total cash and cash equivalents235,260 227,295 7,965 — 
Short-term investments:
U.S. Treasury bills221,362 221,362 — — 
Corporate debt securities94,533 — 94,533 — 
Commercial paper442,743 — 442,743 — 
U.S. Agency bonds89,939 — 89,939 — 
Total short-term investments848,577 221,362 627,215 — 
Long-term investment:
ORIC Pharmaceuticals, Inc.3,465 3,465 — — 
Total$1,087,302 $452,122 $635,180 $— 
December 31, 2021
TotalLevel 1Level 2Level 3
Assets
Cash and cash equivalents:
Cash$19,347 $19,347 $— $— 
Money market funds393,736 393,736 — — 
Total cash and cash equivalents413,083 413,083 — — 
Short-term investments:
U.S. Treasury bills162,228 162,228 — — 
Corporate debt securities235,958 — 235,958 — 
Commercial paper621,979 — 621,979 — 
U.S. Agency bonds58,092 — 58,092 — 
Total short-term investments1,078,257 162,228 916,029 — 
Long-term investment:
ORIC Pharmaceuticals, Inc.8,218 — — 8,218 
Total$1,499,558 $575,311 $916,029 $8,218 

The Company’s investments in Level 1 assets are valued based on publicly available quoted market prices for identical securities as of December 31, 2022 and 2021. The Company determines the fair value of Level 2 related securities with the aid of valuations provided by third parties using proprietary valuation models and analytical tools. These valuation models and analytical tools use market pricing or prices for similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers.

The Company’s long-term investment in ORIC as of December 31, 2021 was considered a Level 3 fair value measurement and utilized a combination of the Asian Protective Put Option and Finnerty Put Option fair value techniques with unobservable inputs of 69% volatility and an expected term of 0.1 years to determine the discount for lack of marketability of 5.0%. In the first quarter of 2022, the eighteen-month lock-up period expired, and because ORIC common stock is quoted in an active market, it meets the criteria of a Level 1 investment. In the first quarter of 2022, the Company transferred the investment in ORIC from a Level 3 fair value measurement to a Level 1 fair value measurement. See Note 10 for further details on the license agreement with ORIC.

The following table represents the changes in estimated fair value of the Company’s Level 3 investment (in thousands):

Balance as of December 31, 2020
$15,629 
Change in fair value(7,411)
Balance as of December 31, 2021
$8,218 
Change in fair value at lock-up expiration (3,100)
Transfer from Level 3 to Level 1 at lock-up expiration(5,118)
Balance as of December 31, 2022
$— 

Other than the investment in ORIC described above, there were no transfers between fair value measurement levels in the years ended December 31, 2022 and 2021.